CBD oil | Leaf Boutique: body & mind
    • Home
    • Blog
    • Shop
    • English
      • Português
      • Español

    Cart

    Your cart is currently empty.

    Return to shop

    Leaf Boutique

    2 weeks ago

    Leaf Boutique
    Exosomal formulation of cannabidiol (CBD) inhibits lung cancer proliferation and enhances uptake and tumor targetingLung cancer remains a leading cause of cancer-related deaths, with treatment specificity posing a major challenge. Thus, we aim to repurpose cannabidiol (CBD) as an antitumor agent, delivered via tumor-targeted exosomes (Exo). We demonstrated that oral CBD administration inhibited orthotopic lung tumor growth by ∼60% (p < 0.01), with enhanced efficacy (∼80%; p < 0.001) achieved using folic acid-functionalized exosomes loaded with CBD. We hypothesized that the enhanced antitumor efficacy is due to 1) increased accumulation at the tumor site due to FA-targeting; 2) improved cellular uptake of CBD via exosomal delivery; and 3) modulation of mechanistic pathways by CBD. To evaluate tumor targeting, FA-Exo labeled with Alexa Fluor-750 (AF750) were administered orally to tumor-bearing mice. Single doses of free AF750, Exo-AF750, and FA-Exo-AF750 were compared (n=3 per group). After 12 hr, mice were euthanized and imaged ex vivo using Odyssey LiCor Imager. For bioavailability studies, female C57BL/6 mice were given a single oral dose of 40 mg/kg CBD or ExoCBD, and tissue CBD levels were quantified 4 hr post-administration. Additionally, ER stress modulation by CBD was assessed in A549 lung cancer cells through analysis of key markers. FA-Exo-AF750 exhibited 3-fold higher signal in tumor tissues compared to non-functionalized exosomes (p<0.01). In bioavailability studies, ExoCBD demonstrated significantly higher CBD levels in the liver (5-fold) and mammary pads (10-fold) compared to free CBD (p<0.001). Notably, free CBD was undetectable in plasma, whereas ExoCBD achieved plasma CBD levels of 500 ng/mL, suggesting enhanced bioavailability and prolonged circulation time. In A549 lung cancer cells, CBD downregulated key ER stress markers, including PERK, IRE1α, BiP, CHOP, Calnexin, and PDI, anti-inflammatory marker NFκB and oncogenic CB2. Furthermore, combination of CBD with paclitaxel (PAC) substantially reduced the IC50 value of PAC against both drug-sensitive (12.5 to 5 nM) and drug-resistant (325 to 80 nM) A549 cells compared to PAC alone. In fact, the activity of PAC and CBD was synergistic against A549 cells, as shown by the combination index (CI = 0.62) calculated using Calcusyn software. Importantly, CBD reversed PAC resistance by downregulating MDR-1 in drug-resistant A549 cells. Overall, tumor-targeted exosomal formulations significantly enhance CBD’s bioavailability, tumor accumulation, and therapeutic efficacy. Combined with its ability to overcome chemotherapy resistance, these findings highlight the promise of CBD-loaded exosomes as a novel therapeutic against lung cancer. ... See MoreSee Less

    aacrjournals.org

    aacrjournals.org

    View on Facebook
    · Share

    Share on Facebook Share on Twitter Share on Linked In Share by Email

    leafboutique2 leaf_boutique @leafboutique2 ·
    5 Feb

    Discovering the Potential of Cannabidiol for Cosmeceutical Development at the Cellular Level #mdpipharmaceuticals via @Pharmaceut_MDPI

    Reply on Twitter 1887253896151826811 Retweet on Twitter 1887253896151826811 Like on Twitter 1887253896151826811 Twitter 1887253896151826811
    leafboutique2 leaf_boutique @leafboutique2 ·
    3 Feb

    Cannabidiol (CBD) Acts as an Antioxidant on Gardnerella vaginalis, Resulting in Reduced Metabolic Activity, Loss of Survivability, and Elimination of Biofilms #mdpiantibiotics via @antibioticsmdpi

    Reply on Twitter 1886393332961567178 Retweet on Twitter 1886393332961567178 Like on Twitter 1886393332961567178 Twitter 1886393332961567178

    Cannabis Chronicles

    cannabis___chronicles

    📰 Your go-to source for all things cannabis:
    • Breaking News & Updates
    • Cutting-edge Research & Insights
    • Fun Facts &Trivia
    • Community Highlights
    📰 Tailored Antipsychotics Lower Cannabis Psycho 📰 Tailored Antipsychotics Lower Cannabis Psychosis Relapse, Swedish Study Shows • LAI antipsychotics, clozapine, and oral aripiprazole are linked to a lower relapse risk. • Consistent antipsychotic use decreases hospitalizations in cannabis-induced psychosis. • Real-world findings emphasize treatment adherence for improved outcomes. A Swedish study involving 1772 patients diagnosed with cannabis-induced psychosis showed that using antipsychotic medications significantly cuts the risk of psychosis relapse. In particular, long-acting injectables, clozapine, and oral aripiprazole proved most effective, suggesting that adherence and tailored treatment strategies are key to better recovery outcomes. Could more strategic use of these medications pave the way for improved care? 🤔💡https://pubmed.ncbi.nlm.nih.gov/40326094/
    Cannabis Linked to 73% More ER Visits in Gastropar Cannabis Linked to 73% More ER Visits in Gastroparesis Patients • Cannabis use linked to higher emergency and hospital visits in gastroparesis patients • Cannabis users showed lower rates of diagnostic endoscopy (EGD) • Patients using cannabis tended to be younger and had more comorbidities (diabetes, mood/anxiety disorders) A large-scale study of 41,374 gastroparesis patients from the TriNetX network explored the impact of cannabis use. Despite its potential benefits—anti-emetic and appetite-stimulating properties—cannabis was associated with a 73% increase in emergency visits and a 44% rise in hospitalizations, while EGD usage was slightly reduced. These findings call for a careful assessment of cannabis in gastroparesis management given the current limited clinical evidence. Should we rethink cannabis as a treatment option in gastro care? 🤔🍃 https://pubmed.ncbi.nlm.nih.gov/40197432/
    📰 Medicinal Cannabis: CBD Soothes Anxiety Quick 📰 Medicinal Cannabis: CBD Soothes Anxiety Quickly, Yet THC May Worsen Mental Health • High doses of CBD showed short-term relief for anxiety symptoms • CBD + THC combinations helped improve sleep and ease withdrawal • THC, when not carefully dosed, may worsen certain mental health outcomes A recent systematic review analyzing 49 controlled studies from 15 countries revealed that medicinal cannabis exhibits mixed effects on mental health. While clinical trials noted dose-dependent adverse events—especially with THC use—naturalistic studies reported symptom improvement following THC use. The review, which covered various diagnoses from anxiety to psychosis, underscores that although medicinal cannabis can offer immediate relief for some symptoms, no long-lasting benefits were established. How might future research balance these short-term benefits with the observed mental health risks? 🤔💡 https://pubmed.ncbi.nlm.nih.gov/40186931/
    📰 Medical Cannabis Yields Nearly 50% IBD Remiss 📰 Medical Cannabis Yields Nearly 50% IBD Remission, Study Finds • Medical cannabis showed notable improvements in inflammatory bowel disease symptoms. • Approximately half of the subjects in the cannabis group achieved complete remission. A recent study published in Digestive Diseases investigated the effects of medical cannabis on inflammatory bowel disease. The findings revealed that patients treated with cannabis experienced significant symptom improvement compared to a placebo group. In fact, complete remission was observed in nearly half of the subjects receiving cannabis, highlighting its potential beneficial role in managing this condition. The research, conducted by experts including T Naftali and colleagues, adds to the growing evidence supporting alternative treatment approaches for complex inflammatory disorders 🌿. Could cannabis become an integral part of future IBD therapies? 🤔 https://karger.com/ddi/article-abstract/32/4/468/96037
    📰 Exploring the Genetic Link Between Schizophre 📰 Exploring the Genetic Link Between Schizophrenia and Cannabis Use • Genetic risk for schizophrenia may also predispose individuals to increased cannabis use. • Cannabis consumption might serve as a contributing factor in the development of schizophrenia. • The relationship between genetic predisposition and cannabis use highlights a complex interplay of risk factors. A recent study by experts RA Power, KJH Verweij, and M Zuhair, published in nature.com, suggests that individuals genetically prone to schizophrenia not only face a higher risk of the disorder but may also be more likely to engage in cannabis use. While cannabis has been implicated as a component cause of schizophrenia, the study raises intriguing questions on whether its use, influenced by genetic predisposition, could in turn elevate psychosis risk. 🤔💡 How might understanding this bidirectional relationship shape future mental health strategies? https://www.nature.com/articles/mp201451
    📰 Cannabis Vapor Alters Lung Genes in Cancer an 📰 Cannabis Vapor Alters Lung Genes in Cancer and Immunity Pathways • Cannabis vaping safety is under scrutiny • Exposure alters genes linked to cancer, oxidative stress, and immune response • Changes occur without triggering DNA damage A recent study used three lung cell models to mimic cannabis vapor exposure on alveolar epithelial cells. The researchers found that while cells maintained in an air-liquid interface naturally expressed critical surfactant and barrier genes, acute cannabis vapor exposure significantly modified pathways related to cancer and metabolism. Notably, these changes did not come with DNA damage but did affect the body’s oxidative stress response and immunity. 🤔💡 How might these findings shape future cannabis vaping policies and respiratory health guidelines? https://doi.org/10.1007/s10565-025-09997-3
    Cannabidiol Fine-Tunes Ion Channels and GPCRs to B Cannabidiol Fine-Tunes Ion Channels and GPCRs to Balance Neural Activity • Cannabidiol impacts both ion channels and G protein-coupled receptors • Findings relate to conditions like epilepsy (especially Dravet syndrome) and autism • Balancing synaptic excitation and inhibition is key to curbing neurological dysfunction This article explores how cannabidiol may influence brain excitability by targeting specific molecular channels and receptors. Focusing on disorders such as epilepsy and autism spectrum disorder (ASD), the study highlights how imbalances in synaptic excitation and inhibition contribute to these conditions. In particular, Dravet syndrome—a severe epilepsy form linked to sodium channel mutations—is examined via a mouse model, offering insights into how adjusting these pathways might restore neural balance. Could this deepen our understanding of therapeutic strategies for challenging neurological disorders? ⚗️🧠 https://pubmed.ncbi.nlm.nih.gov/40048808/
    What's behind CBD's surprising antibacterial power What's behind CBD's surprising antibacterial powers? 🌿💉👀 Did you know that Cannabidiol (CBD) has antibacterial properties? 💥 Recent research reveals the mechanism behind CBD's ability to combat Gram-positive bacteria. 🤔 Researchers analyzed the effects of CBD on three types of bacteria: Bacillus licheniformis, Staphylococcus aureus, and Enterococcus faecium. The results showed that CBD: Disrupted bacterial cell walls and membranes 💥 Changed proteomic and metabolic profiles ⚗️ Inhibited biosynthesis of primary and secondary metabolites 🔍 The study provides valuable insights into the antibacterial mechanism of CBD, which may lead to its development as an antibiotic alternative. 🌟 💡 Highlights: - CBD has promising antibacterial effects against Gram-positive bacteria. - The compound disrupts bacterial cell walls and membranes. - CBD's antibacterial mechanism shares similarities with known agents but differs in detail. 📚 Study published by authors Zeng, Wang, Tang, Liu, Zhang, Chu, Chen, and Ma.
    Follow on Instagram
    • Privacy
    • RETURNS & REFUNDS
    • Terms & Conditions